Previous 10 | Next 10 |
home / stock / avcnf / avcnf news
TORONTO, April 13, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development and commercialization of plant-derived medical and pharmaceutical cannabinoid-based products, is pleas...
Avicanna (OTCQX:AVCNF) on Tuesday said it entered a five-year exclusive distribution agreement with Bio-Gate to expand its (CBD) derma-cosmetics line Pura H&W into the EU. maker Avicanna, which makes plant-derived cannabinoid-based products, and health technology company Bi...
The exclusive distribution agreement includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio The products will be commercialized through Bio-Gate’s existing distribution channels with initial launches planned for Germany, Austria, and Switzerla...
$3.3M in revenue representing 108% Y-Y growth, significant growth in finished product sales Total of 4 brands, 16 SKU’s and 35 “cannabis 2.0” listings across medical and retail channels in Canada Expansion of international footprint with entrance int...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna &...
Tetra Bio-Pharma (OTCQB:TBPMF), a development-stage biopharmaceutical company focused on cannabinoid-derived candidates, announced on Monday that Health Canada greenlighted an amendment to a Phase 1 study designed to evaluate cannabidiol (CBD) in adults. The company has partnered with Dr. Jut...
Avicanna (OTCQX:AVCNF) announced the execution of a non-binding term sheet with Tetra Bio-Pharma (OTCQB:TBPMF) to evaluate the potential of a strategic partnership for cannabinoid- pharmaceutical products. Per the terms, the two companies are set to collaborate in the registration and commerc...
TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercializati...
TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercializat...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ...
News, Short Squeeze, Breakout and More Instantly...
This marks the first export into Asia, the 18 th international market for Aureus branded products and 21 st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ( “Avicanna” or the “Company” ...
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based prod...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...